Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia

Elizabeth A. Griffiths, Hetty E. Carraway, Namrata S. Chandhok, Thomas Prebet

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Acute myeloid leukemia (AML) is primarily a disease of older adults. Many older patients with AML are not candidates for intensive chemotherapy regimens aimed at inducing remission before transplantation. The prognosis for this patient population remains poor, with 5-year overall survival (OS) rates of less than 10 %. At present, there is no standard of care, and clinical trials should be considered. Hypomethylating agents often are the mainstay of treatment in this setting; however, improved genetic profiling and risk stratification based on molecular, biological, and clinical characteristics of AML enhance the ability to identify an individual patient's risk and can refine therapeutic options. Over the past 2 years, several novel agents have been approved for AML patients in either the frontline or relapsed settings. Additional agents have also shown promising activity. It is becoming a challenge for physicians to navigate these different options and select the optimal therapy or combination of therapies. The aim of this review is to summarize the available information to assist with treatment decisions for leukemia patients who are not suitable for intensive chemotherapy.

Original languageEnglish (US)
Article number106339
JournalLeukemia Research
StatePublished - Apr 2020


  • Acute myeloid leukemia
  • Elderly
  • Hypomethylating agents
  • Mutations
  • Targeted agents

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this